This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Christine Esau, Ph.D.
Vice President, Biology at Arrowhead Pharmaceuticals


Christine Esau is Vice President of Biology at Arrowhead Pharmaceuticals, which develops RNA medicines that treat intractable diseases by silencing the genes that cause them. Dr. Esau has more than twenty years experience in the discovery and development of a broad range of RNA-based therapeutics utilizing multiple modalities. Previously she oversaw preclinical activities at Genevant Sciences and Arcturus Therapeutics for a portfolio of siRNA and mRNA therapeutic programs. She performed pioneering work in microRNA targeting and biology at Ionis Pharmaceuticals and Regulus Therapeutics, moving several programs for cardiometabolic and infectious disease from discovery biology to development candidate selection. Dr. Esau also served as Chief Scientific Officer of AptamiR Therapeutics, developing a microRNA-based therapy for obesity. Dr. Esau earned a B.S. degree in biology from Caltech and a Ph.D. from MIT.

Agenda Sessions

  • Preclinical Profile of ARO-SOD1, An siRNA therapy for SOD1-ALS